| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID748132 | Inhibition of auto-PARsylation of GST-tagged TNKS2 PARP domain (947 to 1162) (unknown origin) expressed in Escherichia coli BL21(DE3) after 2 hrs by LC/MS analysis | 2013 | Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
| Fragment-based ligand design of novel potent inhibitors of tankyrases. |
| AID418723 | Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID418725 | Cytotoxicity against human Lu cells after 72 hrs by sulforhodamine B assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID418724 | Cytotoxicity against human LNCAP cells after 72 hrs by sulforhodamine B assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID748135 | Binding affinity to TNKS2 PARP domain (947 to 1162) (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as thermal stabilization at 1 mM by differential scanning flourimetric analysis | 2013 | Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
| Fragment-based ligand design of novel potent inhibitors of tankyrases. |
| AID34980 | Compound was tested for inhibition of crude aldose reductase obtained from rat lens, at the concentration of 100 uM | 1986 | Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
| Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. |
| AID418720 | Inhibition of human quinone reductase 2 expressed in Escherichia coli BL21(DE3) incubated at 23 degC by MTT assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID418721 | Inhibition of aromatase after 30 mins by fluorescence assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID418722 | Cytotoxicity against mouse Hepa-1c1c7 cells after 72 hrs by sulforhodamine B assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1798975 | QR2 Assay and IC50 Value Determination from Article 10.1021/jm801335z: \\Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.\\ | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
| Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |